Drug Profile


Alternative Names: AZD-1152

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Acetamides; Antineoplastics; Fluorobenzenes; Pyrazoles; Quinazolines
  • Mechanism of Action Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 01 Mar 2017 AstraZeneca completes a phase I trial for Solid tumours (Late-stage disease) in USA (IV) (NCT00338182)
  • 31 Dec 2011 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA and European Union (IV)
  • 31 Dec 2011 Discontinued - Phase-II for Acute myeloid leukaemia in USA, European Union, Japan and Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top